UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2023
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification) |
(Address of principal executive offices) (Zip Code)
(Registrant’s Telephone Number, Including Area Code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On June 4, 2023, the Board of Directors (the “Board”)
of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), expanded Class II of the Board from one to two directors and
appointed Ms. Haya Taitel to fill the resulting vacancy. Ms. Taitel will serve as a director until the Company’s 2025 Annual Meeting of Shareholders and until her successor shall have been elected and qualified, subject to her earlier death,
resignation, retirement, disqualification or removal. Ms. Taitel is expected to serve on the Board’s Science Affairs Committee.
Ms. Taitel, age 60, has over 30 years of global C-level biopharma commercial and strategic executive experience. Ms. Taitel currently
serves as the Head of Sanofi’s Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC,
where she contributed to the launch of Rezurock®, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led Kadmon Board’s Executive Commercial Committee. From 1997 to 2012, Ms. Taitel had held
various commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women’s healthcare. Ms. Taitel holds a Master of Science, Pharmacology, (PharmD
equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel.
There are no arrangements or understandings between Ms. Taitel and any other person pursuant to which Ms. Taitel was appointed as a
director of the Company. The Board has determined that Mrs. Taitel is independent under the applicable rules of the Securities and Exchange Commission (the “SEC”)
and the Nasdaq Stock Market.
Since the beginning of Company’s last fiscal year, the Company has not engaged in any transaction, or any currently proposed
transaction, in which Ms. Taitel had or will have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K promulgated by the SEC.
Ms. Taitel will participate in the Company’s standard non-employee director compensation arrangements which were approved by the
Company’s shareholders in October 2021 and include the right to annual cash payments with respect to Board and applicable committee service and an annual grant of options under the Company’s 2018 Equity Incentive Plan.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
ENTERA BIO LTD.
|
|||
|
Date: June 7, 2023
|
By:
|
/s/ Miranda Toledano
|
|
|
Name: Miranda Toledano
Title: Chief Executive Officer
|
|||